Aviva PLC Chemo Centryx, Inc. Transaction History

Aviva PLC

$36.8 Billion
Q3 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 10, 2021	SELL	$9.59 - $50.88 $220,790 - $1.17 Million	-23,023 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$49.53 - $68.4 $40,466 - $55,882	-817 Reduced 3.43%	23,023 $1.18 Million
Q4 2020 Feb 10, 2021	SELL	$47.25 - $65.16 $913,153 - $1.26 Million	-19,326 Reduced 44.77%	23,840 $1.48 Million
Q3 2020 Nov 12, 2020	BUY	$46.35 - $61.69 $2 Million - $2.66 Million	43,166 New	43,166 $2.37 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviva PLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviva PLC with notifications on news.